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ABSTRACT 
 
Monocyte chemo attractant protein (MCP)-1/chemokine (C-C motif) ligand (CCL) 2 (CCL2) 
secreted from white adipose tissue (WAT) in obesity has been reported to contribute to tissue 
macrophage accumulation and insulin resistance by inducing a chronic inflammatory state. 
MCP-1 has been shown to be elevated in the fatty liver of lipoatrophic A-ZIP- transgenic 
(A-ZIP-Tg) mice. Treatment of these mice with the CC chemokine receptor (CCR) 2 antagonist 
has been shown to ameliorate the hyperglycemia, hyperinsulinaemia and hepatomegaly, in 
conjunction with reducing liver inflammation. However, since CCR2 antagonists can block not 
only MCP-1 but also MCP-2 (CCL8) and MCP-3 (CCL7), it remains unclear whether MCP-1 
secreted from the liver could contribute to hyperglycemia, hyperinsulinaemia and hepatomegaly 
in conjunction with liver inflammation, as well as to the M1 and M2 states of macrophage 
polarization. To address these issues, I analyzed the effects of targeted disruption of MCP-1 in 
A-ZIP-Tg mice.  MCP-1 deficiency alone or per se resulted in a significant amelioration of 
insulin resistance in A-ZIP-Tg mice, which was associated with a suppression of extracellular 
signal-regulated protein kinase (ERK)-1/2 and p38 mitogen-activated protein kinase 
(p38MAPK) phosphorylation in liver. Although MCP-1 deficiency did not reduce the 
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expression of macrophage markers, it increased the expression of the genes encoding M2 
macrophage markers such as Arg1 and Chi3l3, as well as significantly reducing the 
triacylglycerol content of livers from A-ZIP-Tg mice. My data clearly indicated that MCP-1 
deficiency improved insulin resistance and hepatic steatosis in A-ZIP-Tg mice and was 
associated with switching macrophage polarization and suppressing ERK-1/2 and p38MAPK 
phosphorylation. 
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INTRODUCTION  
 
Obesity is a medical condition in which excess body fat has accumulated to the extent that it 
may have an adverse effect on health, leading to reduced life expectancy and/or increased 
health problems. Strong positive correlations exist between degree of adiposity and several 
obesity-associated disorder such as hypertension, atherosclerosis and glucose intolerance. 
Obesity increasing in much of the modern world (particularly in the Western world) and 
medical expenses for obesity leads to be a social problem. Expansion of adipose tissue is shown 
in obesity. Adipose tissue used to be thought to be a simple lipid accumulating tissue. Recently, 
it was revealed that adipose tissue was composed of not only adipocytes but also pre-adipocytes, 
macrophages, endothelial cells and fibroblasts, which are called stromal-vascular fraction 
(SVF). Adipocytes, also known as white fat cells, secrete many proteins called adipokines such 
as adiponectin, visfatin lipoprotein lipase and leptin. In addition, hypertrophic adipocytes 
caused by obesity secret inflammatory molecules such as TNF-α, IL-6 and monocyte chemo 
attractant protein -1 (MCP-1) (Fig. 1-1). Obesity is also associated with increased infiltration of 
macrophages into the adipose tissues. These adipose tissue macrophages (ATMs) are currently 
considered to be a major cause of obesity-associated chronic low-grade inflammation via the 
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secretion of a wide variety of inflammatory molecules [1, 2], including TNF-α, IL-6 [3] and 
MCP-1. These inflammatory molecules may have local effects on white adipose tissue (WAT) 
physiology as well as potential systemic effects on other organs that culminate in insulin 
resistance, metabolic syndrome and atherosclerosis. Although both hypertrophied adipocytes 
and infiltrated macrophages produce inflammatory cytokines, the extent of the amounts of 
secreted inflammatory cytokines from infiltrated macrophages which exist in SVF were higher 
than those from hypertrophied adipocytes [4]. Furthermore, Ito et al showed the process of 
secretion of inflammatory molecules and macrophage infiltration. They showed  that MCP-1 
mRNA expression was increased in hypertrophied adipocytes prior to macrophage 
accumulation in diet-induced obese mice. Thus, it was suggested that increase of MCP-1 
mRNA expression in adipocyte was the trigger of macrophage infiltration in adipose tissue [5] 
(Fig. 1-2).   
 Among the inflammatory molecules up regulated in the adipose tissues of obese 
animals and humans, MCP-1 is a member of the cysteine–cysteine (C-C) chemokine family and 
promotes the migration of inflammatory cells by chemotaxis and integrin activation [6]. Both 
Mcp-1 (also known as Ccl2) mRNA expression in WAT and plasma MCP-1 levels have been 
found to correlate positively with the degree of obesity in the individual [7]. In addition, 
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increased production of MCP-1 in WAT precedes the production of other macrophage markers 
during the development of obesity [8]. Mice overproducing MCP-1 in adipocytes showed 
macrophage recruitment in WAT and exhibited insulin resistance in the skeletal muscles (SKM) 
and liver (Fig. 1-3)[9]. Regarding the mechanisms, it was reported that MCP-1 stimulates the 
phosphorylation of extracellular signal-regulated protein kinase (ERK) through the C-C 
chemokine receptor (CCR) 2 [10] and activation of ERK-1/2 induces insulin resistance via 
decreased tyrosine phosphorylation of insulin receptor beta (IR-β) [9] as well as increased 
serine phosphorylation of IRS-1 [11]. 
Macrophage activation has been operationally defined across two separate polarization 
states: M1 and M2. M1, or ‘classically activated’, macrophages are induced by 
proinflammatory mediators such as lipopolysaccharide, whereas M2, or ‘alternatively activated’, 
macrophages generate high levels of anti-inflammatory cytokines such as IL-10, 
Arginase-1(Arg1), Chitinase 3-like 3 (Chi3l3) and TGF-β (Fig. 1-4)[12]. It was previously 
reported that disruption of MCP-1, or its receptor CCR2, in obese mice resulted in decreased 
macrophage infiltration in WAT and improved metabolic function [13, 14]. Moreover, ATMs 
from obese Ccr2-deficient mice produce M2 markers at levels similar to those seen in lean mice 
[14]. These data suggest that the MCP-1/CCR2 axis contributes to macrophage polarization. 
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Therefore, the phenotypic switch in ATM polarization is thought to lead to amelioration of 
insulin resistance.  
 In contrast to obesity, lipoatrophy is caused by a deficiency of WAT and is 
characterized by severe hepatic steatosis and insulin resistance. Lipoatrophy has been classified 
into four main categories: acquired partial lipoatrophy, acquired generalized lipoatrophy, 
familial partial lipoatrophy and congenital generated lipoatrophy. Lipoatrophy is also acquired 
after antiretroviral drug therapy. It is estimated that only a few thousand patients have this rare 
condition worldwide, although robust epidemiological data are not available. In addition, there 
have been no approved therapies for the treatment of metabolic abnormalities associated with 
lipoatrophy, with a combination of dietary modification, anti-diabetic medications and 
lipid-lowering agents used in the management of the condition. Due to lack of adipose tissue, 
there is almost no plasma leptin, one of the adipokines in lipoatrophy [15]. Recently, 
leptin-replacement clinical trial by using metreleptin, an analogue of human leptin, showed a 
sustained beneficial effect on diabetes and lipid control in lipoatrophy patients [16]. In near 
future, metreleptin therapy could be a first approval for lipoatrophy. As leptin also plays a 
regulatory role in immunity, inflammation, and hematopoiesis [17], it might lead to chronic 
inflammation in metreleptin treated lipoatrophy patients. Moreover, there is a concern about 
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emergence of neutralizing antibody for metreleptin. Thus, another treatment should be 
necessary. 
Moitra and colleagues have generated lipoatrophic A-ZIP transgenic (A-ZIP-Tg) mice, 
which are profoundly insulin resistant and hyperlipidaemic [18–20]. These mice express a 
dominant-negative protein, termed A-ZIP, under the control of the adipose-specific aP2 
enhancer/promoter. This protein prevents the DNA binding of B-ZIP transcription factors of 
both the C/EBP and Jun families. A-ZIP Tg mice have almost no white adipose tissue. They are 
initially growth delayed, but by week 12, surpass their littermates in weight. The mice eat, drink, 
and urinate copiously, have decreased fecundity, premature death, and frequently die after 
anesthesia. In addition, these mice exhibit severe hepatic steatosis and at the same time a 
chronic state of inflammation as indicated by high systemic levels of inflammatory cytokines 
such as IL-1β, IL-6, IL-12 and MCP-1 [21–23]. At the very least, MCP-1 is most abundantly 
expressed in the liver from A-ZIP-Tg mice [23]. Moreover, treatment of the lipoatrophic 
A-ZIP-Tg mice with a CCR2 antagonist has been shown to ameliorate the hyperglycaemia, 
hyperinsulinaemia and hepatomegaly, in conjunction with reducing liver inflammation. 
However, since CCR2 antagonist can block not only MCP-1, but also MCP-2 (chemokine [C-C 
motif] ligand [CCL] 8) and MCP-3 (also known as CCL7), it remains unclear whether MCP-1 
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secreted from liver could contribute to hyperglycaemia, hyperinsulinaemia and hepatomegaly in 
conjunction with liver inflammation, as well as to M1/M2 polarisation. 
In this study, I hypothesised that MCP-1 secreted from the liver might also play an 
important role in the regulation of macrophage polarisation and insulin resistance-causing 
kinases such as ERK and p38 mitogen-activated protein kinase (p38MAPK) in liver. To address 
these issues, I analysed the effects of a targeted disruption of MCP-1 in lipoatrophic A-ZIP-Tg 
mice. I showed for the first time that a targeted disruption of MCP-1 alone in lipoatrophic 
diabetic A-ZIP-Tg mice resulted in decreased ERK-1/2 and p38MAPK phosphorylation and 
increased alternative M2 activation of macrophages, with at the same time an amelioration of 
insulin resistance and hepatic steatosis. 
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Fig. 1-1 Adipokines 
Adipocytes secrete many proteins called adipokines such as adiponectin, visfatin lipoprotein 
lipase and leptin. In addition, hypertrophic adipocytes caused by obesity secret inflammatory 
molecules such as TNF-α, IL-6 and MCP-1. 
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Fig. 1-2 Process of the acquirement of metabolic syndrome such as insulin resistance and 
atherosclerosis. 
Hypertrophied adipocytes produce MCP-1 and induce migration of monocytes from blood 
vessels. Migrated monocytes are changed to activated macrophages by stimulation of MCP-1. 
These activated macrophages induce secretion of inflammatory molecules such as MCP-1 and 
TNF-α and it brings much activated macrophage infiltrations in adipose tissue. These negative 
inflammatory feedback called vicious cycle lead to become metabolic syndrome such as insulin 
resistance and atherosclerosis. 
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Fig. 1-3 Overexpression of MCP-1 in adipose tissue results in systemic insulin resistance 
through both paracrine and endocrine pathways. 
Overexpression of MCP-1 in adipose tissue induced macrophage infiltration and at the same 
time increased insulin resistance causing adipokines, such as tumor necrosis factor-alpha (TNF-
α), interleukin-6 (IL-6) and non-esteryzed free-fatty acids (NEFA), which resulted in systemic 
insulin resistance. 
 
Fig. 1-4 Macrophage polarization in response to inflammatory signals. 
Macrophage activation has been operationally defined across two separate polarisation states: 
M1 and M2. M1, or ‘classically activated’, macrophages are induced by pro-inflammatory 
mediators such as lipopolysaccharide, whereas M2, or ‘alternatively activated’, macrophages 
generate high levels of anti-inflammatory cytokines such as IL-10, Arginase and TGF-β. 
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PURPOSE OF THIS STUDY 
 
To address the effects and mechanisms of MCP-1 derived from tissues other than WAT, such as 
fatty liver for the regulation of whole body insulin sensitivity, hepatic steatosis and macrophage 
polarization by using lipoatrophic A-ZIP transgenic mice. 
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MATERIALS AND METHODS 
 
Generation of A-ZIP-Tg×Mcp1
−/−
 mice  
A-ZIP/F-1 (A-ZIP-Tg) mice were generous gifts from C. Vinson of the National 
Cancer Institute at Frederick, MD, USA. Mcp1−/− mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA) and C57BL/6 mice from CLEA Japan (Fujinomiya, 
Shizuoka, Japan). A-ZIP/F-1 mice were on an FVB/N (FVB) background. MCP-1 
homozygous-knockout mice were on a C57BL/6 background, which had been backcrossed to 
C57BL/6 mice for 10 generations.  
To generate A-ZIP-Tg Mcp1+/− mice, conceptuses that were obtained by in vitro 
fertilisation of ova from Mcp1−/− mice and sperm from A-ZIP-Tg mice were implanted into 
pseudo-pregnant foster mothers as previously described [24]. To generate A-ZIP-Tg×MCP-1 
knockout (Mcp1−/−) mice and Mcp1−/− mice, conceptuses that had been obtained by in vitro 
fertilisation of ova from MCP-1 homozygous-knockout mice and sperm from 
A-ZIP-Tg×MCP-1 heterozygous-knockout mice were implanted into pseudo-pregnant foster 
mothers. To generate wild-type (WT) mice and A-ZIP-Tg mice, conceptuses that had been 
obtained by in vitro fertilisation of ova from C57BL/6 mice and sperm from A-ZIP-Tg×MCP-1 
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heterozygous-knockout mice were implanted into pseudo-pregnant foster mothers. All 
experiments in this study were conducted on female mice. 
In this study, I generated WT mice, Mcp1−/− mice, A-ZIP-Tg mice and 
A-ZIP-Tg×Mcp1−/− mice which were on an FVB/B6 F2 background. This breeding strategy 
was used to improve the viability of the offspring as A-ZIP-Tg mice on an FVB background 
have poor survival [18].  
 
Mice  
Mice were housed in cages and maintained on a 12-h light/dark cycle. For all 
experiments, the diet was standard chow (CE-2; CLEA Japan) with the following composition: 
25.6% (wt/wt) protein, 3.8% fibre, 6.9% ash, 50.5% carbohydrates, 4% fat and 9.2% water [24–
26]. The animal care and use procedures were approved by the Animal Care Committee of the 
University of Tokyo. 
 
Northern blot analysis  
Northern blotting was carried out according to the method described previously [25, 
26]. Total RNA was extracted from various tissues with TRIzol reagent according to the 
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manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). Total RNA (15 µg) was loaded 
onto a 1.3% agarose gel and transferred to a nylon membrane (Hybond N+; GE Healthcare Life 
Sciences, Hino, Tokyo, Japan). MCP-1 coding sequence cDNA was used as the probe template. 
The cDNA probe template of MCP-1 was prepared by RT-PCR using specific primers. The 
forward primer was 5'-CCATGCAGGTCCCTGTC-3' and the reverse primer was 
5'-CTAGTTCACTGTCACAC-3', as previously described [9]. The corresponding bands were 
quantified by exposure of BAS2000 to the filters and measurement with BAStation software 
(Fuji Film, Minato-ku, Tokyo, Japan). 
 
Real-time quantitative PCR  
For real-time quantitative PCR analysis, cDNA synthesised from total RNA was 
analysed. For quantification of gene expression, a set of predesigned primers and probes for 
each gene (Assays-on-Demand; Applied Biosystems, Carlsbad, CA, USA) were used.  Mouse 
MCP-1: Mm00441242_m1, 
mouse MCP-2: Mm01297183_m1, 
mouse MCP-3: Mm00443113_m1, 
mouse CCR2: Mm99999051_gH, 
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mouse Emr1: Mm00802530_m1, 
mouse CD68: Mm00839636_g1, 
mouse Chi3l3: Mm00657889_mH, 
mouse TGF-β: Mm03024053_m1, 
mouse Arg1: Mm01190441_g1,  
mouse PPARa: Mm00440949_m1, 
mouse Acyl-coA oxidase: Mm00443579_m1, 
mouse UCP2: Mm00495907_g1, 
mouse SREBP1c: Mm00550338_m1, 
mouse SCD1: Mm00772290_m1. 
The primer sets and the probe for mouse cyclophilin were as follows:  
the forward primer was 5'-GGTCCTGGCATCTTGTCCAT-3',  
the reverse primer was 5'-CAGTCTTGGCAGTGCAGATAAAA-3';  
and the probe was 5'-CTGGACCAAACACAAACGGTTCCCA-3'.  
The relative amount of each transcript was normalised to the amount of mouse cyclophilin 
mRNA. 
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Blood sample assays and in vivo glucose homeostasis  
Glucose tolerance tests (GTTs) were conducted as previously described with slight 
modifications [25, 26]. For the GTTs, mice were deprived of food for 6 h and then orally 
administered with D-glucose (1.5 g per kg body weight). Plasma glucose and plasma triglycerol 
(TG) levels in the fed state were determined using a glucose B-test and TG E-type test (Wako 
Pure Chemical Industries, Yodogawa-ku, Osaka, Japan), respectively. Plasma insulin levels 
were measured with an insulin immunoassay (Shibayagi, Shibukawa, Gunma, Japan). Plasma 
MCP-1 levels in the fed state were measured using a mouse immunoassay kit (Pierce 
Biotechnology Inc, Rockford, IL, USA).  
 
Hyperinsulinemic-euglycemic clamp study  
Clamp studies were carried out between A-ZIP-Tg mice and A-ZIP-Tg×Mcp1-/- mice. 
Data represent means±SEM (n=3 per group).*P<0.05 vs A-ZIP-Tg mice. 2-3 days before the 
study, an infusion catheter was inserted into the right jugular vein under general anesthesia with 
sodium pentobarbital. Studies were performed on mice under conscious and unstressed 
conditions after a 6-h fast. A primed continuous infusion of insulin (Humalin R, Lilly) was 
given (5.0 mill units/g/min), and the blood glucose concentration, monitored every 5 min, was 
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maintained at (11 m moll/l) by administration of glucose (5g of glucose per 10 mL enriched to 
20% with [6,6-2H2] glucose (Sigma)) for 120 min. Blood was sampled via tail tip bleeds at 90, 
105, and 120 min for determination of exogenous glucose infusion rates (GIR), hepatic glucose 
production (HGP) and rate of glucose disappearance (Rd). 
 
Antibodies  
Mouse monoclonal anti-phosphotyrosine antibody 4G10 (αPY) was purchased from 
Merck Millipore (Billerica, MA, USA). Rabbit polyclonal antibody to IR-β was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal antibodies against 
ERK-1/2, phospho-ERK-1/2 (Thr202/Tyr204), p38MAPK, phosphor-p38MAPK 
(Thr180/Tyr182), insulin, hemoxygenase-1, Akt and phospho-Akt (Ser-473) were purchased 
from Cell Signaling Technology (Danvers, MA, USA). Rabbit polyclonal antibodies against 
IRS-1 and phospho-IRS-1 (Ser-612) were purchased from Cell Signaling Technology (Danvers, 
MA, USA). 
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Immunoblotting and immunoprecipitation  
Immunoblotting and immunoprecipitation were conducted as previously described [27]. 
In brief, in the fed state, the skeletal muscles from the hind limbs or livers were removed. The 
samples were homogenised in ice-cold 1% Nonidet P-40-buffer (25 mmol/l Tris-HCL [pH 7.4], 
10 mmol/l sodium orthovanadate, 10 mmol/l EGTA and 1 mmol/l phenylmethylsulfonyl 
fluoride) and centrifuged. For immunoblotting, muscle homogenates containing 5 mg of total 
protein or liver homogenates containing 15 mg of total protein were incubated with the 
indicated primary antibodies and horseradish peroxidase-conjugated anti-mouse-IgG secondary 
antibody and were detected with enhanced chemiluminescence (ECL) reagent (GE Healthcare 
Life Sciences). For immunoprecipitation, muscle homogenates containing 5 mg of total protein 
or liver homogenates containing 15 mg of total protein were also incubated with the indicated 
antibodies followed by addition of protein G-Sepharose. The immunoprecipitates were washed 
with 1% Nonidet P-40-buffer 3 times. The immunoprecipitates were subjected to 
immunoblotting with the indicated primary antibodies and horseradish peroxidase-conjugated 
anti-mouse-IgG secondary antibody and were detected with ECL reagent. 
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Histological analyses and TG content in liver  
Livers from WT mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1−/− mice were fixed 
overnight in 10% formalin (vol./vol.). Samples were routinely embedded in paraffin. 
Approximately 5 µm-thick slices obtained from these liver samples were stained with 
haematoxylin and eosin. The liver homogenates were extracted and their TG content was 
determined as previously described [24]. 
 
Macrophage staining in liver  
Livers from WT mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1−/− mice were fixed 
overnight in 10% formalin (vol./vol.). Samples were routinely embedded in paraffin. 
Approximately 5 µm-thick slices obtained from these liver samples were stained with 
anti-hem-oxygenase-1 (HO-1) as previously described [28].  
 
Insulin staining in islet  
Islets from WT mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1−/− mice were fixed 
overnight in 10% formalin (vol./vol.). Samples were routinely embedded in paraffin. 
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Approximately 5 µm-thick slices obtained from these islet samples were stained by using 
anti-insulin antibody as previously described [29]. 
 
Cuff injury model 
 The cuff injury model was used as described previously [30]. The left femoral artery 
was isolated from surrounding tissues, and after loosely sheathing it with a 2.0-mm 
polyethylene cuff mode of PD-50 tubing, the cuff was tied in place with an 80 suture. The cuffs 
were larger than the vessels and did not obstruct blood flow. 2 weeks after cuff placement, 
vessels were foxed with 10% formalin and embedded in paraffin. Continuous cross-sections 
were cut from one end of the cuffed portion to the other end and were stained for elastic fibers 
and with hematoxylin and eosin. The thickness of the neo intimal formation was observed by 
digital microscope camera (Olympus, Tokyo, japan).  
 
Statistical analysis  
Results are expressed as means±SEM. The Student’s t test was performed to compare 
two groups. Values p<0.05 were considered statistically significant.  
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RESULTS 
 
No differences in body weight, plasma glucose levels and liver weight between WT mice 
and Mcp1
−/−
 mice.  
As there was no difference in body weight, plasma glucose levels in the fed state and 
liver weight between WT mice and Mcp1−/− mice (Fig. 2), and previous reports had also shown 
that the body weight, adipose weight, insulin tolerance and glucose tolerance of Mcp1−/− mice 
fed normal chow did not differ from those of WT control mice [13], I analyzed and compared 
the WT mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1−/− mice.  
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Fig. 2 There was no difference in body weight, plasma glucose levels in the fed state and liver 
weight between WT mice and Mcp1
−/−
 mice  
Body weight of WT mice and Mcp1
−/−
 mice were measured at 9 weeks of age, as indicated (a). 
Liver weight of WT and Mcp1
−/−
 15-week-old mice (b). Plasma parameters of glucose (c) and 
insulin (d) were measured in 15-week-old WT and Mcp1
−/−
 mice. Data represent means±SEM 
(WT mice, n=5, Mcp1
−/−
 mice, n=5). **P<0.01 vs WT mice.  
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Gender difference in MCP-1 deficient A-ZIP-Tg mice.  
In the beginning of this study, I compared the gender phenotypic difference of MCP-1 
deficient A-ZIP-Tg mice. The increase in plasma MCP-1 level of A-ZIP-Tg male mice (Fig. 3a) 
was similar to that of A-ZIP-Tg female mice (Fig. 3a). MCP-1 deficiency significantly 
ameliorated hyperglycaemia (Fig. 3b) but not hyperinsulinaemia in A-ZIP-Tg male mice (Fig. 
3c). Plasma glucose levels and plasma insulin levels during the GTTs were not significantly 
changed in male A-ZIP-Tg×Mcp1−/− mice as compared with male A-ZIP-Tg mice (Fig. 3d,e), 
suggesting that MCP-1 deficiency in male A-ZIP-Tg mice did not ameliorate glucose 
intolerance. These data suggested that the insulin-sensitive phenotype of A-ZIP-Tg- Mcp1−/− 
mice was prominent in female mice compared with male mice. I thus used female mice in this 
study. 
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Fig. 3 MCP-1 deficiency in male A-ZIP-Tg mice ameliorates hyperglycemia but not 
hyperinsulinaemia. 
Plasma parameters of MCP-1 (a), glucose (b) and insulin (c) were measured in 15-week-old 
WT (white bars), A-ZIP-Tg (black bars), and A-ZIP transgenic MCP-1 knockout 
(A-ZIP-Tg×Mcp1
−/−
) (grey bars) mice. Plasma glucose (d) and plasma insulin (e) during GTT 
(1.5 g glucose per kilogram body weight) in WT (white circles), A-ZIP-Tg (white triangles) and 
A-ZIP-Tg×Mcp1
−/−
 (black triangles) in 15-week-old mice. Data represent means ± S.E.M. (WT 
mice, n = 5; A-ZIP-Tg mice, n = 16; and A-ZIP-Tg×Mcp1
−/−
 mice, n = 11). * P < 0.05 versus 
A-ZIP-Tg×Mcp1
−/−
mice. 
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Plasma MCP-1 concentration and Mcp-1 mRNA expression in fatty liver were increased 
in lipoatrophic A-ZIP-Tg mice  
Many previous studies have reported elevated plasma MCP-1 concentration and Mcp-1 
mRNA expression in WAT of obese and diabetic mice [9, 13, 31–33]. As reported [23], plasma 
MCP-1 concentrations were significantly elevated in A-ZIP-Tg mice compared with WT mice 
(Fig. 4a). A previous study showed that, in WT mice, Mcp-1 mRNA was not detected in any 
tissues [13], whereas in A-ZIP-Tg mice, as previously reported [23], Mcp-1 mRNA was most 
abundantly expressed in the liver among all the tissues I examined, including brown adipose 
tissue (BAT), except for WAT, because lipoatrophic A-ZIP-Tg mice still have BAT but not WAT, 
as reported in other studies [14, 18, 19, 23] (Fig. 4b). It has been reported that MCP-1 is 
abundantly expressed in Kupffer cells, as well as in hepatocytes in the liver [34, 35] 
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Fig. 4 Plasma MCP-1 concentration and tissue distribution of Mcp1 mRNA in A-ZIP-Tg mice. 
(a) Plasma concentrations of MCP-1 were measured in WT (white bars), A-ZIP-Tg (black bars) 
and A-ZIP-Tg×Mcp1
−/−
 (grey bars) 15-week-old mice in the fed state. Data are means±SEM. 
WT mice, n=5; A-ZIP-Tg mice, n=17; A-ZIP-Tg×Mcp1
−/−
 mice, n=16. **p<0.01 vs A-ZIP-Tg 
mice. ND, not detected. (b) Northern blot analysis of Mcp1 mRNA expressed in liver, SKM, 
BAT, Hypo (hypothalamus) and ovary of 15-week-old A-ZIP-Tg mice 
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MCP-1 deficiency decreased body weight gain and liver weight in A-ZIP-Tg mice 
To clarify the pathophysiological roles of elevated MCP-1 levels in lipoatrophic 
A-ZIP-Tg mice, I generated A-ZIP-Tg×Mcp1−/− mice. MCP-1 deficiency in A-ZIP-Tg mice 
resulted in decreased body weight compared with A-ZIP-Tg mice (Fig. 5a), although the food 
intake of A-ZIP-Tg×Mcp1−/− mice was not significantly different from that seen in A-ZIP-Tg 
mice (Table 1). Furthermore, the liver weight of A-ZIP-Tg×Mcp1−/− mice was decreased 
compared with that of A-ZIP-Tg mice (Fig. 5b).  
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Table 1. 
Food intake of A-ZIP-Tg mice and A-ZIP-Tg×Mcp1-/- mice. 
 A-ZIP-Tg A-ZIP-Tg×Mcp1
-/-
 mice 
Food intake (g/day) 5.93±0.18 4.31±0.09* 
Food intake (g/day/BW) 0.20±0.01 0.17±0.02 
Body weight (g) 29.67±1.35 25.33±0.98**  
Average food intake per day, average food intake per day per body weight and average body 
weight of A-ZIP-Tg and A-ZIP-Tg×Mcp1
-/-
 were measured from 11-14 weeks of age. Data 
represent means±SEM ( A-ZIP-Tg mice, n=17 and A-ZIP-Tg×Mcp1
-/-
 mice, n=16). *P<0.05, 
**P<0.01 vs A-ZIP-Tg mice.  
 
 
 
 
 
Table 2. 
Tissue weight of A-ZIP-Tg mice and A-ZIP-Tg×Mcp1
-/-
 mice. 
 A-ZIP-Tg A-ZIP-Tg×Mcp1-/- mice 
Body weight (g) 31.53±0.76 26.91±0.80** 
Liver weight (g) 3.12±0.27 2.22±0.29** 
BAT weight (g) 0.03±0.01 0.02±0.01 
Pancreas weight (g) 0.45±0.02 0.42±0.04 
Body weight, liver weight, BAT weight and Pancreas weight of  A-ZIP-Tg and 
A-ZIP-Tg×Mcp1-/-  were measured at 15-week-old mice. Data represent means±SEM 
(A-ZIP-Tg mice, n=17 and A-ZIP-Tg×Mcp1-/-  mice, n=16). *P<0.05, **P<0.01 vs A-ZIP-Tg 
mice. 
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Fig. 5 Body weight and liver weight of WT mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1−/− 
mice.  
(a) Body weight of WT mice (white circles), A-ZIP-Tg mice (white triangles) and 
A-ZIP-Tg×Mcp1−/− mice (black triangles) were measured from 9 to 14 weeks of age, as 
indicated. (b) Liver weight of WT (white bars), A-ZIP-Tg (black bars) and A-ZIP-Tg×Mcp1−/− 
(grey bars) in 15-week-old mice. Data are means±SEM. WT mice, n=5; A-ZIP-Tg mice, n=17; 
A-ZIP-Tg×Mcp1−/− mice, n=16. **p<0.01 vs A-ZIP-Tg mice  
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MCP-1 deficiency ameliorated glucose tolerance in lipoatrophic A-ZIP-Tg mice 
A-ZIP-Tg×Mcp1−/− mice showed amelioration of hyperglycaemia, hyperinsulinaemia 
and hypertriacylglycerolaemia compared with A-ZIP-Tg mice (Fig. 6a–c). To further clarify the 
effects of MCP-1 deficiency in A-ZIP-Tg mice on glucose tolerance and insulin sensitivity, I 
performed GTTs. Plasma glucose levels and plasma insulin levels during the GTTs were 
significantly lower in A-ZIP-Tg×Mcp1−/− mice than in A-ZIP-Tg mice (Fig. 6d,e), suggesting 
that MCP-1 deficiency in A-ZIP-Tg mice partially ameliorated glucose intolerance. In WT mice, 
plasma insulin levels were increased after glucose administration, whereas they were 
remarkably decreased in A-ZIP-Tg and A-ZIP-Tg- Mcp1−/− mice, consistent with previous 
observations that prolonged hyperinsulinaemia due to severe insulin resistance can result in 
decreased glucose-stimulated insulin-secretion, in particular decreased early-phase insulin 
secretion [36]. A hyperinsulinaemic-euglycaemic clamp study revealed that the glucose infusion 
rate was significantly increased in A-ZIP-Tg- Mcp1−/− mice compared with A-ZIP-Tg mice 
(Fig. 7), indicating that disruption of MCP-1 in A-ZIP-Tg mice could ameliorate insulin 
resistance. 
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Fig. 6 MCP-1 deficiency in A-ZIP-Tg mice ameliorates glucose intolerance and insulin 
sensitivity.  
Plasma values for glucose (a), insulin (b) and TG (c) were measured in 15-week-old WT (white 
bars), A-ZIP-Tg (black bars) and A-ZIP-Tg×Mcp1−/− (grey bars) mice. Plasma glucose (d) and 
plasma insulin (e) during GTT (1.5 g glucose per kilogram body weight) in WT (white circles), 
A-ZIP-Tg (white triangles) and A-ZIP-Tg×Mcp1−/− (black triangles) in 15-week-old mice. Data 
are means±SEM. WT mice, n=5; A-ZIP-Tg mice, n=17; A-ZIP-Tg×Mcp1−/− mice, n=16. 
**p<0.01 vs A-ZIP-Tg mice 
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Fig. 7 Hyperinsulinemic-euglycemic clamp study.  
Clamp studies were carried out between A-ZIP-Tg mice and A-ZIP-Tg- Mcp1−/− mice. Data 
represent means±SEM (n=3 per group).*P<0.05 vs A-ZIP-Tg mice. 2-3 days before the study, 
an infusion catheter was inserted into the right jugular vein under general anesthesia with 
sodium pentobarbital. Studies were performed on mice under conscious and unstressed 
conditions after a 6-h fast. A primed continuous infusion of insulin (Humalin R, Lilly) was 
given (5.0 mill units/g/min), and the blood glucose concentration, monitored every 5 min, was 
maintained at 11 (mmol/l) by administration of glucose (5g of glucose per 10 mL enriched to 
20% with [6,6-2H2] glucose (Sigma)) for 120 min. Blood was sampled via tail tip bleeds at 90, 
105, and 120 min for determination of exogenous glucose infusion rates (GIR) (a), hepatic 
glucose production (HGP) (b) and rate of glucose disappearance (Rd) (c). 
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Livers from A-ZIP-Tg×Mcp1
−/−
 mice did not decrease the expression of macrophage 
marker genes in liver, SKM , BAT and also did not reduce of the number of macrophages 
in liver.   
Many studies have demonstrated that macrophage infiltration and levels of 
proinflammatory cytokines such as MCP-1 and TNF-α are increased in WAT of human obese 
individuals and several models of rodent obesity [37, 38]. I examined whether the expression of 
macrophage marker genes would be elevated in other tissues than WAT, such as liver, SKM and 
BAT, in A-ZIP-Tg mice. The mRNA expressions of Mcp-1, Mcp-3 (Ccl7), Ccr2, Emr1 
(EGF-like module containing, mucin-like, hormone receptor-like 1) and Cd68 (CD68 antigen) 
were increased in the liver (Fig. 8a–e), SKM (Fig. 10a-e) and BAT (Fig. 11a-e) of A-ZIP-Tg 
mice compared with WT mice. The mRNA expressions of Mcp-2 were significantly increased 
in the liver and BAT of A-ZIP-Tg mice compared with those of WT mice. MCP-1 deficiency 
did not significantly decrease the expressions of Mcp-2 in the liver, SKM and BAT in 
A-ZIP-Tg mice (Fig. 12). Next, I conducted 1-OH staining for detection of the actual number of 
macrophages in liver [28]. Same as gene expression data, actually, the number of 1-OH staining 
positive macrophages were increased in liver from A-ZIP-Tg mice but it did not decreased in 
MCP-1 deficient A-ZIP-Tg mice (Fig. 9) 
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Livers from A-ZIP-Tg×Mcp1
−/−
 mice showed increased markers of alternatively activated 
M2 macrophages  
Unexpectedly, MCP-1 deficiency did not decrease the expression of macrophage 
marker genes in other tissues than WAT, such as the liver, SKM and BAT in A-ZIP-Tg mice. 
Because a previous report showed that ATMs isolated from obese Ccr2-deficient mice 
expressed alternatively activated M2-macrophage markers [14], I hypothesised that livers from 
A-ZIP-Tg×Mcp1−/− mice might contain M2-polarised macrophages more abundantly. 
Interestingly, characteristic M2-macrophage marker genes such as Chi3l3, Arg1 and Tgfb1 were 
significantly increased in livers from A-ZIP-Tg×Mcp1−/− mice (Fig. 8f–h). In contrast to liver, 
characteristic M2-macrophage marker genes such as Chi3l3, Arg1 and Tgfb1 were not 
significantly changed in SKM and BAT from A-ZIP-Tg×Mcp1−/− mice (Fig. 10, 11f-h). Thus, 
MCP-1 deficiency did not reduce macrophage markers but rather induced macrophages to shift 
to a M2-polarised state in livers from A-ZIP-Tg mice. These data suggest that MCP-1 
deficiency enhances M2 polarisation in livers of A-ZIP-Tg mice. 
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Fig. 8 Effects of MCP-1 deficiency on the expression of macrophage marker genes in liver.  
Mcp-1 (a), Ccr2 (b), Mcp-3 (c), Emr1 (d) and Cd68 (e) mRNA levels and the mRNA ratio of 
Chi3l3/Cd68 (f), Arg1/Cd68 (g) and Tgf-β/Cd68 (h) in livers from WT (white bars), A-ZIP-Tg 
(black bars) and A-ZIP-Tg×Mcp1−/− (grey bars) in 15-week-old mice in the fed state were 
analysed by real-time quantitative PCR. Data are means±SEM. WT mice, n=5; A-ZIP-Tg mice, 
n=17; A-ZIP-Tg×Mcp1−/− mice, n=16. *p<0.05 vs A-ZIP-Tg mice 
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Fig. 9 Macrophage staining in liver.  
Livers from WT mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1
−/−
 mice were fixed overnight in 
10% formalin (vol./vol.). Samples were routinely embedded in paraffin. Approximately 5 
µm-thick slices obtained from these liver samples were stained with anti-hem-oxygenase-1 
(HO-1). Representative sections of livers were stained with HO-1 (Scale bars, 100 µm) from 
WT, A-ZIP-Tg and A-ZIP-Tg×Mcp1
−/−
 in 15-week-old mice.  
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Fig. 10 Effects of MCP-1 deficiency on the expression of macrophage marker genes in SKM.  
Mcp-1 (a), Ccr2 (b), Mcp-3 (c), Emr1 (d), Cd68 (e) mRNA levels and the mRNA ratio of 
Chi3l3/Cd68 (f), Arg1/Cd68 (g) and TGF-β/Cd68 (h) in SKM in 15-week-old WT (white bars), 
A-ZIP-Tg (black bars), and A-ZIP transgenic MCP-1 knockout (A-ZIP-Tg×Mcp1−/−) (grey 
bars) mice in the fed state were analyzed by real-time quantitative PCR. Data represent 
means±SEM (WT mice, n=5; Mcp1−/− mice, n=5).*P<0.05, **P<0.01 vs A-ZIP-Tg mice. 
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Fig. 11 Effects of MCP-1 deficiency on the expression of macrophage marker genes in BAT.  
Mcp-1 (a), Ccr2 (b), Mcp-3 (c), Emr1 (d), Cd68 (e) mRNA levels and the mRNA ratio of 
Chi3l3/Cd68 (f), Arg1/Cd68 (g) and TGF-β/Cd68 (h) in BAT in 15-week-old WT (white bars), 
A-ZIP-Tg (black bars), and A-ZIP transgenic MCP-1 knockout (A-ZIP-Tg×Mcp1
−/−
) (grey 
bars) mice in the fed state were analyzed by real-time quantitative PCR. Data represent 
means±SEM (WT mice,  n=5; Mcp1
−/−
 mice, n=5).*P<0.05, **P<0.01 vs A-ZIP-Tg mice. 
40 
 
 
 
 
Fig. 12 Effects of MCP-1 deficiency on the expression of MCP-2 gene expessions in liver, 
SKM and BAT.  
Mcp-2 mRNA levels in liver (a), SKM (b) and BAT (c) from WT (white bars), A-ZIP-Tg (black 
bars) and A-ZIP-Tg×Mcp1−/− (grey bars) in 15-week-old mice in the fed state were analyzed by 
real-time quantitative PCR. Data represent means±SEM (WT mice, n=5; A-ZIP-Tg mice, n=17 
and A-ZIP-Tg×Mcp1−/− mice, n=16). *P<0.05 vs A-ZIP-Tg mice. 
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MCP-1 deficiency decreased liver TG content in A-ZIP-Tg mice  
It was previously reported that A-ZIP-Tg mice showed dyslipidaemia and severe 
hepatic steatosis [18]. Liver weights were markedly reduced in A-ZIP-Tg×Mcp1−/− mice 
compared with A-ZIP-Tg mice (Fig. 5b). Representative histological sections of livers showed 
that MCP-1 deficiency decreased TG accumulation (Fig. 13a). I subsequently determined that 
the TG content in livers from A-ZIP-Tg×Mcp1−/− mice was significantly less than that in livers 
from A-ZIP-Tg mice (Fig. 13b). To clarify the mechanism by which hepatic steatosis was 
improved, I studied the expression of genes involved in lipid and energy metabolism and found 
that expression of Ppara mRNA tended to be increased and expression of genes involved in 
energy dissipation such as Ucp2 significantly increased in A-ZIP-Tg- Mcp1−/− mice compared 
with A-ZIP-Tg mice, whereas the expression of genes involved in lipogenesis such as Srebp-1c 
(Srebf1) and Scd-1 was not significantly changed (Fig. 14). 
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Fig. 13 Histological analysis and TG content of liver.  
(a) Sections of livers were stained with haematoxylin and eosin (Scale bars, 100 µm). (b) TG 
content of livers from WT (white bars), A-ZIP-Tg (black bars) and A-ZIP-Tg×Mcp1−/− (grey 
bars) mice. Data are means±SEM. WT mice, n=5; A-ZIP-Tg mice, n=17; A-ZIP-Tg×Mcp1−/− 
mice, n=16. **p<0.01 vs A-ZIP-Tg mice 
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Fig. 14 Effects of MCP-1 deficiency on the expression of genes involved in fatty acid  
oxidation and synthesis in liver. 
Ppara (a), Acyl-coA oxidase (b), Ucp-2 (c), Srebp-1c (d) and Scd-1 (e) mRNA levels  
in livers from WT (white bars), A-ZIP-Tg (black bars) and A-ZIP-Tg×Mcp1−/− (grey bars) in 
15-week-old mice in the fed state were analyzed by real-time quantitative PCR. Data represent 
means±SEM (WT mice, n=5; A-ZIP-Tg mice, n=17 and A-ZIP-Tg×Mcp1−/− mice, n=16). 
*P<0.05 vs A-ZIP-Tg mice. 
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MCP-1 deficiency enhanced insulin signalling in livers of A-ZIP-Tg mice  
Previous studies have reported that MCP-1 induces phosphorylation of ERK through 
activation of CCR2 in SKM, myocytes, kidney and leukaemia cells [9, 10, 39, 40]. Moreover, 
Bost et al reported that mice lacking ERK-1 were protected from high-fat diet-induced obesity 
and insulin resistance [41]. Thus, I hypothesised that inhibition of ERK signalling would 
improve insulin signalling in A-ZIP-Tg mice, so I studied phosphorylation of ERK-1/2 in livers 
from A-ZIP-Tg mice and A-ZIP-Tg×Mcp1−/− mice. In fact, ERK-1/2 and p38MAPK 
phosphorylation were significantly increased in livers from A-ZIP-Tg mice compared with WT 
mice. Conversely, phosphorylation of ERK-1/2 was decreased in livers from 
A-ZIP-Tg×Mcp1−/− mice compared with A-ZIP-Tg mice (Fig. 15a). I next examined the effects 
of MCP-1 deficiency on insulin signalling in livers from A-ZIP-Tg mice. In livers from 
A-ZIP-Tg×Mcp1−/− mice, tyrosine phosphorylation of IR-β and serine phosphorylation of Akt 
were significantly increased compared with that seen in A-ZIP-Tg mice (Fig. 16). Moreover, 
Ser 612 in IRS-1 has been reported to be phosphorylated by ERK [41], which would result in 
inhibition of insulin signalling. The amount of Ser 612 phosphorylation in IRS-1 was 
significantly decreased in livers from A-ZIP-Tg×Mcp1−/− mice compared with A-ZIP-Tg mice 
(Fig. 17). Furthermore, in SKM from A-ZIP-Tg×Mcp1−/− mice, tyrosine phosphorylation of 
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IR-β was significantly, and serine phosphorylation of Akt tended to be, increased compared 
with A-ZIP-Tg mice (Fig. 18).  
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Fig. 15 MCP-1 deficiency in livers from A-ZIP-Tg mice results in the phosphorylation of 
ERK-1/2 and p38MAPK. 
Phosphorylation of ERK1/2 (a) and p38MAPK (b) in livers from WT, A-ZIP-Tg and 
A-ZIP-Tg×Mcp1−/− 15-week-old mice in the fed state were analysed by immunoblotting. The 
relative amount of each protein was normalised to the total amount of ERK-1/2 or p38MAPK 
and the ratio is shown. Data are means±SEM (n=3 per group). *p<0.05, **p<0.01 vs WT or 
A-ZIP-Tg mice. 
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Fig. 16 MCP-1 deficiency in livers from A-ZIP-Tg mice results in increased insulin 
signalling.  
Tyrosine phosphorylation of IR-β (a) and phosphorylation of Akt (Ser-473) (b) in livers from 
WT, A-ZIP-Tg and A-ZIP-Tg×Mcp1
−/−
 15-week-old mice in the fed state were analysed by 
immunoblotting. The relative amount of each protein was normalised to the total amount of 
IR-β or Akt and the ratio is shown. Data are means±SEM (n=3 per group). *p<0.05, **p<0.01 
vs WT or A-ZIP-Tg mice 
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Fig. 17 MCP-1 deficiency in livers from A-ZIP-Tg mice results in the phosphorylation of 
Ser-612 of IRS-1.  
Total amount of IRS-1 (a) and phosphorylation of Ser-612 in IRS-1 (b) in livers from A-ZIP-Tg 
(white bars) and A-ZIP-Tg×Mcp1−/− (black bars) 15-week-old mice in the fed state were 
analyzed by immunoprecipitation. The relative amount of each protein was normalized to the 
total amount of IRS-1. Data represent means ± S.E.M. (n = 3 per group).* P < 0.05 versus 
A-ZIP-Tg mice. 
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Fig. 18 MCP-1 deficiency in SKM from A-ZIP-Tg mice results in increased insulin signaling.  
Tyrosine phosphorylation of IR-β (a) and phosphorylation of Akt (Ser-473) (b) in SKM from 
A-ZIP-Tg (white bars) and A-ZIP-Tg×Mcp1−/−(black bars) 15-week-old mice in the fed state 
were analyzed by immunoblotting. The relative amount of each protein was normalized to the 
total amount of IR-β or Akt. Data represent means±SEM (n=3 per group).*P<0.05, **P<0.01 vs 
A-ZIP-Tg mice. 
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MCP-1 deficiency decreased islet hypertrophy and increased insulin staining positive cells. 
 Representative histological sections of islets showed that MCP-1 deficiency in 
A-ZIP-Tg mice decreased islet hypertrophy and increased insulin staining positive cells in islet 
(Fig. 19). These results would lead to improvement of glucose-stimulated insulin secretion of 
MCP-1 deficient A-ZIP-Tg mice in OGTT (Fig. 6e).  
 
 
Fig. 19 MCP-1 deficiency decreased islet hypertrophy and increased insulin staining positive 
cells in A-ZIP-Tg mice. 
Islets from WT mice, Mcp1
−/−
 mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1
−/−
 mice were fixed 
overnight in 10% formalin (vol./vol.). Samples were routinely embedded in paraffin. 
Approximately 5 µm-thick slices obtained from these islet samples were stained with 
anti-insulin antibody. Representative sections of islets were stained with anti-insulin antibody 
(Scale bars, 100 µm) from WT mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1
−/−
 mice. 
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Improvement of atherosclerosis in MCP-1 deficient A-ZIP-Tg mice.  
 Previous study showed that CCR2 deficient mice reduced atherosclerosis in cuff 
injured mice (19). Interestingly, although neo intimal formation in aorta of A-ZIP-Tg mice was 
increased, MCP-1 deficient A-ZIP-Tg mice significantly reduced it. (Fig. 20). These results 
suggest that MCP-1 deficiency could atherosclerosis in lipoatrophy patients.     
  
 
 
 
 
 
 
Fig. 20 MCP-1 deficiency showed decreased neo intimal formation in A-ZIP-Tg mice. 
2 weeks after cuff placement, vessels were foxed with 10% formalin and embedded in paraffin. 
Continuous cross-sections of the femoral arteries from A-ZIP-Tg mice and A-ZIP-Tg×Mcp1
−/−
 
mice were cut from one end of the cuffed portion to the other end and were stained for elastic 
fibers and with hematoxylin and eosin. The thickness of the neo intimal formation was observed 
by digital microscope camera. (Black arrows shows the lesions of neo intimal formation) (Scale 
bars, 100 µm) 
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DISCUSSION  
 
MCP-1/CCL2 secreted from WAT in obesity has been reported to contribute to tissue 
macrophage accumulation and insulin resistance by inducing a chronic inflammatory state. 
MCP-1, CCR2 and M1 macrophage marker genes have been shown to be elevated in the fatty 
liver of lipoatrophic A-ZIP-Tg mice. In addition, phosphorylation of ERK1/2 and p38MAPK, 
Scd1 and Acc1 mRNA which contribute to fatty acid synthesis are also increased in the fatty 
liver of A-ZIP-Tg mice (Fig. 21-1). Though I could not identify the source of the induction of 
MCP-1 in the fatty liver of A-ZIP-Tg mice, there is some potential that increase of endogenous 
macrophage infusion such as Kupffer cells could produce MCP-1 in the liver of A-ZIP-Tg mice 
(Fig. 9). Moreover, Mandrekar et al showed that hepatocytes as well as Kupffer cells expressed 
high amounts of MCP-1 mRNA in the liver of alcohol induced liver injury with steatosis [35]. 
Thus, not only endogenous macrophage but also hepatocytes would be the main candidates for 
overproduction of MCP-1 in the liver of A-ZIP-Tg mice. Treatment of these mice with CCR2 
antagonist has been shown to ameliorate their hyperglycaemia, hyperinsulinaemia and 
hepatomegaly, in conjunction with a reduction in liver inflammation. However, since CCR2 
antagonist can block not only MCP-1, but also MCP-2 and MCP-3, it remains unclear whether 
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MCP-1 secreted from liver could contribute to hyperglycaemia, hyperinsulinaemia and 
hepatomegaly in conjunction with liver inflammation, as well as to M1/M2 polarisation. To 
address these issues, I analyzed the effects of targeted disruption of MCP-1 in A-ZIP-Tg mice. 
The insulin-sensitive phenotype of A-ZIP-Tg- Mcp1−/− mice was prominent in female mice 
compared with male mice. It was reported that lipoatrophy associated features include 
polycyctic ovary syndrome in woman [42]. Polycystic ovary syndrome shows excessive 
amounts of androgenic hormons, resulting in insulin resistance, often associated with type 2 
diabetes. Though I did not analyzed, lipoatrophic A-ZIP-Tg mice might show polycystic ovary 
syndrome, which leads to worsen insulin sensitivity. In addition, northern blotting study 
showed MCP-1 was also expressed in the ovary of A-ZIP-Tg mice. Thus, ovariectomy may 
ameliorate insulin resistance of female A-ZIP-Tg mice by blocking MCP-1 excretion from 
ovary. Due to these ovary disorder and MCP-1 expression from ovary might lead to the gender 
difference of insulin resistance of MCP-1 deficient A-ZIP-Tg mice. Furthermore, in other 
cytokine deficient mice, CXC motif chemokine ligand-14 (CXCL-14) mice, the 
insulin-sensitive phenotype after high fat diet feeding was also prominent in female mice but 
not in male mice [43]. These gender difference of cytokine deficient mice for insulin resistance 
might be important for the future study.  In the current study, I showed for the first time that 
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targeted disruption of MCP-1 alone in lipoatrophic diabetic A-ZIP-Tg mice ameliorated insulin 
resistance and hepatic steatosis, which was associated with decreased ERK-1/2 and p38MAPK 
phosphorylation (Fig. 15) and alternative M2 activation of macrophages. However, MCP-1 
deficient A-ZIP-Tg mice also decreased MCP-3 mRNA expression in liver and BAT. MCP-3 is 
located on chromosome 11 in mice and  most closely related to MCP-1, MCP-1 is also located 
in chromosome 11. Thus, reduction of MCP-3 mRNA might be due to transcriptional affect of 
MCP-1 gene deletion. There are few reports of MCP-3 for insulin resistance and diabetes as 
compared with those of MCP-1. MCP-3 mRNA was reported to be increase in adipose tissue of 
obese mice and kidney of type 1 diabetes patients. MCP-3 protein was also increased in urine of 
type 1 diabetes patients with long term renal inflammation [44]. Although both MCP-1 and 
MCP-3 attract monocytes and regulate macrophage function, besides MCP-3, MCP-1 induces 
amylin expression through activation of ERK signaling pathways independent of CCR2. 
Increase of amylin contributes to deterioration of insulin resistance [45]. Thus, MCP-1 would 
more worsen insulin resistance than MCP-3. In this study, MCP-3 mRNA was not significantly 
decreased in SKM of A-ZIP-Tg×Mcp1−/− mice, however, insulin resistance of SKM was 
improved as compared with A-ZIP-Tg mice. According to these evidences, the direct effect of 
MCP-3 for insulin resistance was not stronger than that of MCP-1. Certainly, though I could not 
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exclude the effect for the reduction of MCP-3 to insulin resistance, the improvement of insulin 
resistance in A-ZIP-Tg×Mcp1−/− mice was assessed to be mainly derived from deficiency of 
MCP-1 in A-ZIP Tg mice.   
Although food intake was not significantly different when adjusted by body weight (Table 
1), daily food intake of A-ZIP-Tg×Mcp1−/− mice was decreased as compared with that of A-ZIP 
Tg mice. Thus, pair-feeding, an experimental method in which food intake or energy (calory) 
intake are limited to be same between animal groups would be suitable for this study, but I 
could not conduct it due to concern of poor longevity of A-ZIP Tg mice. The A-ZIP-Tg mice 
with MCP-1 deficiency tended to exhibit increased Ppara and exhibited significantly increased 
Ucp2 expression in the liver (Fig. 14), raising the possibility that the body weight and liver 
weight reduction (Table 2) were due to increased energy expenditure, and that it could also 
contribute to the reduction in liver triacylglycerol content. However, it has been technically 
extremely difficult to prepare enough A-ZIP-Tg×Mcp1−/− mice to unequivocally prove 
increased energy expenditure in these mice. I would like to carry out this experiment in the 
future study. 
 The amounts of tyrosine phosphorylation of IR-β and serine phosphorylation of Akt were 
increased in livers from A-ZIP-Tg×Mcp1−/− mice (Fig. 16). These data suggested that the 
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amelioration of insulin resistance by disruption of MCP-1 in A-ZIP-Tg mice, such as increased 
tyrosine phosphorylation of IR-β and serine phosphorylation of Akt in liver, seemed to be 
related to decreased ERK-1/2 and p38MAPK activation [46], at least in part.  
Although the disruption of MCP-1 in A-ZIP-Tg mice improved insulin resistance, the gene 
expression of macrophage markers such as Emr1 and Cd68 in the liver were not decreased 
compared with those seen in A-ZIP-Tg mice (Fig. 8d,e). It was recently reported that the 
induction of M2 markers in resident macrophages in the liver controls hepatic lipid metabolism 
[47]. In this study, the M2-specific genes Chi3l3 and Arg1 were increased in livers from 
A-ZIP-Tg×Mcp1−/− mice compared with A-ZIP-Tg mice (Fig. 8f,g). These data are consistent 
with the results that ATMs from obese Ccr2-deficient mice express M2 markers at levels similar 
to those found in lean mice [14]. However, treatment with CCR2 antagonist reduced the 
macrophage marker gene Cd68 mRNA and Tnf-α mRNA in the livers of A-ZIP-Tg mice [23]. 
These results might be derived from differences between a chronic and an acute inhibition of 
CCR2 or between targeted disruption of MCP-1 and simultaneous inhibition of 
MCP-1/MCP-2/MCP-3 by CCR2 antagonist in the liver of A-ZIP-Tg mice.  
Previous studies have shown that CCR2 promoted obesity-induced hepatic steatosis in db/db 
mice [48], that a CCR2 antagonist (propagermanium) also reduced liver TG content in db/db 
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mice [49], and that another CCR2 antagonist (RS 504393) ameliorated hepatomegaly but did 
not decrease hepatic TG content significantly (p=0.144) [23]. These results raised the 
possibility that inhibition of MCP-1 and/or MCP-2 and/or MCP-3 by CCR2 inhibition could be 
involved in the suppression of hepatic steatosis. In this study, I showed for the first time that 
targeted disruption of MCP-1 in A-ZIP-Tg mice by itself exhibited decreased liver TG content 
in the liver (Fig. 13b), clearly indicating that MCP-1 plays an important role in the onset of 
hepatic steatosis in the liver in A-ZIP-Tg mice.  
In terms of treatment for lipoatrophy, leptin-replacement clinical trial by using metreleptin is 
on-going. However, there are concern about induction of chronic inflammation and emergence 
of neutralizing antibody for metreleptin. As CCR2 antagonist also prevents inflammation, 
steatosis and insulin resistance, combination therapy of metreleptin and CCR2 antagonist would 
bring additive or synergistic effects for amelioration of lipoatrophy.  
In conclusion, I showed for the first time that targeted disruption of MCP-1 by itself 
ameliorated insulin resistance and hepatic steatosis, and at the same time decreased 
phosphorylation of ERK-1/2 and p38 MAPK (increased tyrosine phosphorylation of IR-β and 
serine phosphorylation of Akt) and induced alternative M2 activation of macrophages in the 
fatty liver from lipoatrophic diabetic A-ZIP-Tg mice (Fig. 21-2). These results suggest that 
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MCP-1 derived from tissues other than WAT, such as fatty liver, could also play an important 
role in the regulation of whole body insulin sensitivity, hepatic steatosis, macrophage 
polarisation and phosphorylation of ERK-1/2 and p38 MAPK (Fig. 21-3). The current study 
also suggests that modulating MCP-1 in the liver would be useful therapy for diabetes and fatty 
liver.  
 
Fig. 21-1 Phenotypes of A-ZIP transgenic mice as compared with wild-type mice.   
Plasma MCP-1 concentrations were significantly increased in A-ZIP-Tg mice and Mcp-1 
mRNA was most abundantly expressed in the liver of A-ZIP-Tg mice. A-ZIP-Tg mice showed 
liver steatosis, hepatomegaly and increase of M1 macrophage infusion, phosphorylation of 
ERK, p38MAPK and lipogenic gene expressions such as Scd1 and Acc1 mRNA in the liver.  
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Fig. 22-2 Phenotypes of MCP-1 deficient A-ZIP transgenic mice as compared with A-ZIP 
transgenic mice.  
MCP-1 deficiency ameliorated insulin resistance and hepatic steatosis at the same time  
decreased phosphorylation of ERK-1/2 and p38MAPK and induced alternative M2 activation  
of macrophages in the liver of lipoatrophic diabetic A-ZIP-Tg mice. These results suggest that  
modulating MCP-1 in the liver would be useful therapy for diabetes and hepatic steatosis. 
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Fig. 22-3 Paracrine and endocrine effects of MCP-1 derived from adipose tissue and liver for  
whole body insulin resistance.   
MCP-1 from adipocytes induce macrophage infiltration and increase insulin resistance causing 
adipokines. MCP-1 from liver also plays an important role in the regulation of hepatic steatosis, 
macrophage recruitment and insulin signaling. Both paracrine and endocrine effects of 
MCP-1from adipocyte and liver could contribute to the development of whole body insulin 
resistance.  
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